Brought to you by:
Societies seek consensus on NIVL management amid ‘paucity of rigorous data’
The diagnosis and management of non-thrombotic iliac vein lesions (NIVL) is the focus of a newly published set of consensus statements from the Vascular Interventional Advances (VIVA) Foundation, the American Venous Forum (AVF), and the American Vein and Lymphatic Society…
Researchers report 30-day outcome data for pair of investigational carotid stenting systems
Thirty-day results from two trials assessing the performance of investigational carotid artery stenting systems—the Neuroguard and the CGuard—were recently presented at VIVA 2023. Stenting with the CGuard embolic protection carotid stent system (InspireMD) in patients with carotid artery stenosis and…
Computer-assisted vacuum thrombectomy system for patients with pulmonary embolism demonstrates ‘rapid, statistically significant’ improvement in RV/LV ratio
Patients undergoing computer-assisted vacuum thrombectomy with the Indigo Aspiration System (Penumbra) for pulmonary embolism (PE) showed 2.7% rates of both major adverse events (MAEs) and major bleeding at 48 hours post-procedure alongside “a significant reduction” in right ventricle/left ventricle (RV/LV)…
Six-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit in acute DVT patients demonstrate ‘promise’
The open-label phase of the DEXTERITY-AFP trial investigating the Bullfrog microinfusion device—which involves the perivenous injection of the anti-inflammatory drug dexamethasone to improve patency and post-thrombotic syndrome (PTS) six months after thrombus removal in symptomatic deep vein thrombosis (DVT) patients—has…
Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’ of deep vein arterialization in no-option CLTI patients
Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia (CLTI) patients were today published in the New England Journal of Medicine (NEJM). The publication confirmed…
Diversifying clinical trials: ‘There needs to be some kind of cultural competency’
The COVID-19 pandemic exposed lingering mistrust in the U.S. healthcare system among patients from minority communities as physicians continue to confront the conundrum of healthcare disparities in terms of outcomes alongside a lack of diversity in clinical trials, a roundtable…
Spotlight: SVS members in the news
Several SVS members have been making moves recently, attracting recognition in the form of awards and promotions. Katherine Gallagher, MD, of the University of Michigan, has been elected to the National Academy of Medicine for her “innovative translational research on…
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66% at six months
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint target of 54%, chief investigator Daniel Clair, MD, told the 2022 Vascular Interventional Advances (VIVA) meeting…
PROMISE I 24-month results ‘validate the benefits of the LimFlow system’
LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for both amputation-free survival and wound healing, a press release reports. The late-breaking data were presented at…
IN.PACT AV DCB sustained ‘superior’ effectiveness in subgroups with high reintervention rates out to two years
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of target lesion primary patency (TLPP) compared to those who underwent standard percutaneous transluminal angioplasty (PTA) through 24…